You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

Hodgkin´s Lymphoma

Showing 1 - 25 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

B-cell Non-Hodgkin's Lymphoma Trial (SHR-A1912; R-Chemo)

Not yet recruiting
  • B-cell Non-Hodgkin's Lymphoma
  • SHR-A1912; R-Chemo
  • (no location specified)
Oct 23, 2023

Non-hodgkin's Lymphoma Trial in Beijing (GNC-035)

Not yet recruiting
  • Non-hodgkin's Lymphoma
  • Beijing, Beijing, China
    Beijing Cancer Hospital
Sep 27, 2023

Hodgkin Lymphoma, Relapse, Refractory Trial in Chapel Hill (Chemotherapy, Cell infusion)

Not yet recruiting
  • Hodgkin Lymphoma
  • +2 more
  • Chapel Hill, North Carolina
    Lineberger Comprehensive Cancer Center
Oct 13, 2023

Hodgkin Lymphoma Trial in Guadalajara (Pentoxifylline, Placebo)

Recruiting
  • Hodgkin Lymphoma
  • Guadalajara, Jalisco, Mexico
    Hospital Civil de Guadalajara Fray Antonio Alcalde
Aug 4, 2022

Leukemia, Stem Cell Transplantation Trial in Munich (FBTA05)

Withdrawn
  • Leukemia
  • Stem Cell Transplantation
  • Munich, Bavaria, Germany
    3. Medizinische Klinik, Klinikum rechts der Isar der TU München
Dec 5, 2022

Hodgkin Lymphoma Trial in Italy (Tislelizumab)

Not yet recruiting
  • Hodgkin Lymphoma
  • Alessandria, IT, Italy
  • +9 more
Aug 4, 2023

Advanced Classical Hodgkin's Lymphoma in Brazil Treated With

Not yet recruiting
  • Hodgkin Lymphoma
  • No Intervention
  • Salvador, Bahia, Brazil
  • +5 more
Oct 23, 2023

Recurrent Anaplastic Large Cell Lymphoma, Recurrent Angioimmunoblastic T-Cell Lymphoma, Recurrent Mature T- and NK-Cell

Active, not recruiting
  • Recurrent Anaplastic Large Cell Lymphoma
  • +10 more
  • Houston, Texas
    M D Anderson Cancer Center
Jan 30, 2023

Aggressive Non-Hodgkin Lymphoma, Ann Arbor Stage I Primary Mediastinal (Thymic) Large B-Cell Cell Lymphoma, Ann Arbor Stage II

Active, not recruiting
  • Aggressive Non-Hodgkin Lymphoma
  • +13 more
  • Columbus, Ohio
    Ohio State University Comprehensive Cancer Center
Aug 18, 2022

Ann Arbor Stage III Non-Hodgkin Lymphoma, Ann Arbor Stage IV Non-Hodgkin Lymphoma, Solid Tumor Trial in New Brunswick

Active, not recruiting
  • Ann Arbor Stage III Non-Hodgkin Lymphoma
  • +2 more
  • New Brunswick, New Jersey
    Rutgers Cancer Institute of New Jersey
Jan 28, 2023

Lymphoma Patients Undergoing CAR-T Cell Therapy: FIL_SAR-CAR

Not yet recruiting
  • Non-hodgkin Lymphoma,B Cell
  • Chimeric Antigen Receptor T-cells (CAR-T) therapy
  • Alessandria, Italy
  • +20 more
Nov 27, 2023

Recurrent Follicular Lymphoma, Recurrent Marginal Zone Lymphoma, Recurrent Nodal Marginal Zone Lymphoma Trial (Acalabrutinib,

Withdrawn
  • Recurrent Follicular Lymphoma
  • +8 more
  • (no location specified)
Jun 2, 2022

Novel Monoclonal Antibodies in B-cell Non-Hodgkin Lymphoma in

Not yet recruiting
  • Non-Hodgkin Lymphoma, B-cell
  • "novel" MAB (alone or in combination)
  • Viagrande, Catania, Italy
  • +57 more
Aug 18, 2023

Lymphoma, Non-Hodgkin, Hodgkin Lymphoma Trial in Worldwide (AZD3470)

Not yet recruiting
  • Lymphoma
  • +2 more
  • Miami, Florida
  • +10 more
Nov 13, 2023

Recurrent Classic Hodgkin Lymphoma, Refractory Classic Hodgkin Lymphoma Trial (procedure, drug, biological, radiation, other)

Not yet recruiting
  • Recurrent Classic Hodgkin Lymphoma
  • Refractory Classic Hodgkin Lymphoma
  • Autologous Hematopoietic Stem Cell Transplantation
  • +13 more
  • (no location specified)
Feb 2, 2023

Hodgkin Lymphoma Molecular Profiling and Clinical Outcomes in

Completed
  • Hodgkin's Disease
    • Louisville, Kentucky
      Norton Cancer Institute
    Dec 14, 2021

    Classical Hodgkin Lymphoma Trial in Seattle (drug, other, biological)

    Recruiting
    • Classical Hodgkin Lymphoma
    • Seattle, Washington
      Fred Hutch/University of Washington Cancer Consortium
    Sep 8, 2022

    Anaplastic Large Cell Lymphoma, Recurrent Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma, Refractory Mature T-Cell and NK-Cell

    Active, not recruiting
    • Anaplastic Large Cell Lymphoma
    • +2 more
    • Laboratory Biomarker Analysis
    • +2 more
    • Duarte, California
    • +1 more
    Jul 26, 2022

    Circulating Tumor DNA Genotyping for Biological Monitoring of

    Active, not recruiting
    • Hodgkin Lymphoma
      • Avellino, Italy
      • +12 more
      Dec 22, 2022

      B-cell Non-Hodgkin Lymphoma Trial in Worldwide (Mosunetuzumab (IV), Mosunetuzumab (SC), Polatuzumab vedotin)

      Recruiting
      • B-cell Non-Hodgkin Lymphoma
      • Mosunetuzumab (IV)
      • +4 more
      • Birmingham, Alabama
      • +28 more
      Jan 6, 2023

      Non-Hodgkin Lymphoma (NHL), Acute Myeloid Leukemia (AML), Multiple Myeloma (MM) Trial in Worldwide (VOB560, MIK665)

      Recruiting
      • Non-Hodgkin Lymphoma (NHL)
      • +2 more
      • Gent, Belgium
      • +9 more
      Mar 18, 2022

      Recurrent B-Cell Non-Hodgkin Lymphoma, Recurrent Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue,

      Suspended
      • Recurrent B-Cell Non-Hodgkin Lymphoma
      • +23 more
      • Columbus, Ohio
        Ohio State University Comprehensive Cancer Center
      Feb 23, 2022

      AIDS-Related Hodgkin Lymphoma, Ann Arbor Stage II Hodgkin Lymphoma, Ann Arbor Stage IIA Hodgkin Lymphoma Trial in France, United

      Active, not recruiting
      • AIDS-Related Hodgkin Lymphoma
      • +11 more
      • Brentuximab Vedotin
      • +4 more
      • La Jolla, California
      • +27 more
      Jul 27, 2022

      Recurrent Anaplastic Large Cell Lymphoma, Recurrent Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma, Recurrent Primary Cutaneous

      Recruiting
      • Recurrent Anaplastic Large Cell Lymphoma
      • +8 more
      • Columbus, Ohio
        Ohio State University Comprehensive Cancer Center
      Apr 6, 2022

      Hodgkin Disease Trial in Worldwide (Brentuximab vedotin, Doxorubicin, Vinblastine)

      Completed
      Has Results
      • Hodgkin Disease
      • Brentuximab vedotin
      • +3 more
      • Aurora, Colorado
      • +13 more
      Jun 17, 2022